Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 791 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Tacrolimus Clear all
Completed Phase 3 Interventional Results available

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

NCT00322101
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
total-body irradiation, allogeneic hematopoietic stem cell transplantation, cyclophosphamide, mycophenolate mofetil, busulfan, cyclosporine, fludarabine phosphate, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, cytogenetic analysis, flow cytometry, fluorescence in situ hybridization, pharmacological study, polymorphism analysis, tacrolimus, methotrexate
Radiation · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Denver, Colorado • Altanta, Georgia • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 26, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal

NCT00896012
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Kidney Biopsy, Rapamune (sirolimus/rapamycin), Tacrolimus
Procedure · Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 26, 2026, 4:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus

NCT03083782
View directory record Official record
Conditions
Venous Thromboembolism, Pharmacokinetics, Healthy
Interventions
Apixaban alone, Cyclosporine, Tacrolimus, Apixaban
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 26, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients

NCT00282568
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus Modified Release (MR), tacrolimus
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
7
States / cities
San Diego, California • Miami, Florida • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 26, 2026, 4:35 AM EDT
Recruiting Phase 2 Interventional

Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

NCT06280950
View directory record Official record
Conditions
Liver Transplant
Interventions
Everolimus, Tacrolimus (continued reduction), Tacrolimus (maintain 50% reduction)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 26, 2026, 4:35 AM EDT
Not listed Phase 4 Interventional

Veloxis de Novo Kidney Transplant ECSWD

NCT03828682
View directory record Official record
Conditions
Kidney Transplantation, Immunosuppression
Interventions
Tacrolimus Extended Release Oral Tablet [Envarsus], Mycophenolate Mofetil, Mycophenolic Acid Oral Product, Tacrolimus, Methylprednisolone, Prednisone, Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]
Drug
Lead sponsor
Simon Tremblay, PharmD, PhD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 26, 2026, 4:35 AM EDT
Recruiting Phase 1 Interventional

Treatment of Antibody-Mediated Rejection (ABMR) With CarBel

NCT06918990
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Carfilzomib, Belatacept
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 26, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients

NCT02866682
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Prograf, Tacrolimus
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 26, 2026, 4:35 AM EDT
Completed No phase listed Observational

Extended Follow-Up After Islet Transplantation in T1D

NCT01369082
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Islet Transplantation
Interventions
Maintenance Immunosuppressive Treatment
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 26, 2026, 4:35 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078
View directory record Official record
Conditions
Chronic Graft-versus-host-disease
Interventions
INCA034176, Best available Treatment (BAT)
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 26, 2026, 4:35 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy

NCT04080076
View directory record Official record
Conditions
Renal Disease
Interventions
Acthar 80 UNT/ML Injectable Solution, Oral Tab Tacrolimus
Drug
Lead sponsor
NephroNet, Inc.
Other
Eligibility
65 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Lawrenceville, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 26, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)

NCT01884571
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Basiliximab, Methylprednisolone, Prednisone, Tacrolimus, Mycophenolate mofetil
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 26, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

NCT00817206
View directory record Official record
Conditions
Renal Failure
Interventions
LCP-Tacro, Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Oct 26, 2026, 4:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention

NCT04503616
View directory record Official record
Conditions
Graft-versus-host Disease
Interventions
Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 26, 2026, 4:35 AM EDT
Terminated Phase 2 Interventional Results available

S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma

NCT00121186
View directory record Official record
Conditions
Lymphoma
Interventions
fludarabine phosphate, melphalan, methotrexate, tacrolimus, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
33
States / cities
Maywood, Illinois • Beech Grove, Indiana • Richmond, Indiana + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Oct 26, 2026, 4:35 AM EDT
Recruiting No phase listed Observational

Pharmacokinetics of Drugs Administered to Children

NCT03481881
View directory record Official record
Conditions
Pediatric ALL
Interventions
Standard of care drug
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2033
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 26, 2026, 4:35 AM EDT
Terminated Phase 4 Interventional Results available

A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity

NCT00983645
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Prograf, Neoral
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 26, 2026, 4:35 AM EDT
Completed Phase 2 Interventional

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00027573
View directory record Official record
Conditions
Kidney Cancer
Interventions
filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
6
States / cities
Scottsdale, Arizona • Indianapolis, Indiana • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 26, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

B Cell Induction in Pediatric Lung Transplantation

NCT02266888
View directory record Official record
Conditions
Lung Transplant
Interventions
Rituximab (Rituxan®), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Palo Alto, California • Boston, Massachusetts • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 26, 2026, 4:35 AM EDT
Not listed Phase 4 Interventional

Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients

NCT00999258
View directory record Official record
Conditions
Glomerular Filtration Rate, Chronic Allograft Nephropathy
Interventions
sirolimus
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2009 · Synced Oct 26, 2026, 4:35 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion

NCT02053545
View directory record Official record
Conditions
Leukemia, Lymphoma, MDS
Interventions
Conditioning Regimen & GVHD Prophylaxis
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 26, 2026, 4:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

NCT00520130
View directory record Official record
Conditions
Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia, Multiple Myeloma
Interventions
Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT), Conditioning Chemotherapy, TMS, FLAG, EPOCH-F, Alemtuzumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 74 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 26, 2026, 4:35 AM EDT
Completed No phase listed Observational

Drug Interaction With Envarsus XR and Grapefruit Juice

NCT03916380
View directory record Official record
Conditions
Kidney Transplant; Complications, Drug Interaction Food
Interventions
Grapefruit Juice
Dietary Supplement
Lead sponsor
Shirley M. Tsunoda
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 26, 2026, 4:35 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

NCT06503731
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 26, 2026, 4:35 AM EDT